R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Neurology - Small molecules (26)

Modality Indication Targets Stage Company Project No. Detail
1 Preclinical development of an HDAC6 inhibitor targeting Axonal Transport dysfunction in Charcot-Marie-Tooth Disease
Small molecules Charco-Marie-Tooth disease HDAC6 Preclinical Chong Kun Dang RS-2025-25454943
2 Phase 2 study of Oral VVZ-2471 for the treatment of chronic neuropathic pain
Small molecules Neuropathic Pain (PHN) 5-HT2AR, mGluR5 Phase 2 Vivozon RS-2025-25454827
3 Development of Preclinical Candidates Targeting Novel TAS2R GPCR for Parkinson's disease
Small molecules Parkinson's disease TAS2R GPCR Candidate DigmBio RS-2025-25453249
4 Discovery of lead compounds targeting TDP43 for treatment of Amyotrophic lateral sclerosis (ALS)
Small molecules ALS TDP43 Hit KIST RS-2025-25453059
5 Nrf2-targeting small molecule candidate development for parkinson's disease
Small molecules Parkinson's Disease Keap1-Nrf2 axis Candidate SPARKBiopharma RS-2025-25449417
6 Development of structurally modified microbial small molecule of multi-MOA for Parkinson's disease
Small molecules Parkinson's disease FKBP (FK506-binding protein) Candidate MolGenBio Co., Ltd. RS-2025-25444385
7 Development of a lead compound for CT contrast agents in the quantitative diagnosis of acute cerebral infarction and establishment of personalized diagnostic and therapeutic strategies for stroke patients
Small molecules Ischemic stroke Fibrin within the thrombus Lead Seoul National University R&DB Foundation RS-2025-02223267
8 Development of a novel small molecule targeting ASK1 for the treatment of Parkinson’s disease
Small molecules Parkinson's disease ASK1 Candidate Naason Science Inc. RS-2025-02213938
9 AAK1 Inhibition for the Treatment of Neuropathic Pain: Identification and Evaluation of Novel Candidates
Small molecules Pain AAK1 Candidate CIMPLRX Co. Ltd. RS-2025-02213667
10 Development of first-in-class tuberous sclerosis brain disease therapeutic targeting Rheb GTPase
Small molecules Tuberous Sclerosis Rheb Hit K-medihub/New drug development center RS-2025-02213662
11 Non-clinical development of new selective allosteric TrkA inhibitor for pain treatment
Small molecules Osteoarthritis pain TrkA, TRPV1 Preclinical Mother’s Pharmaceutical Co., Ltd. RS-2025-02213103
12 Nonclinical efficacy and safety evaluation of an LRRK2 inhibitor candidate for the development of a disease-modifying Parkinson’ s disease therapy and subsequent IND approval
Small molecules Parkinson's disease LRRK2 Preclinical Novorex Inc. RS-2025-02213047
13 Development of Candidate Compounds for Therapeutic Intervention in Ischemic Brain Injury: Targeting MMP-9 Inhibition to Prevent Blood-Brain Barrier Disruption, Neuronal Degeneration, and Neuroinflammatory Responses.
Small molecules Ishemic brain injury MMP-9 Candidate Zincure Corp RS-2025-02182973
14 Non-clinical studies of LMT801 for the treatment of Charcot- Marie-Tooth Disease Type 1A (CMT1A)
Small molecules Charcot-Marie-Tooth disease type 1A NQO1 Preclinical Lmito Therapeutics RS-2025-02073078
15 Development of Lead Compounds for Parkinson’s Disease Treatment by Regulating Adult Neurogenesis through ERRTargeted Small Molecules
Small molecules Parkinson’s disease Estrogen-related receptor gamma Lead CHA university RS-2024-00463446
16 Phase 2a clinical development of Vutiglabridin, a diseasemodifying drug for Parkinson’s disease through PON2-mediated autophagy activation
Small molecules Parkinson’s disease Paraoxonase 2 Phase 2 Glaceum Inc. RS-2024-00459662
17 Evaluating the safety and efficacy of PRG-N-01 in patients with Neurofibromatosis Type 2
Small molecules Neurofibromatosis Type 2 Oncopathogenic neo-TβR1-RKIP interaction Phase 1 PRG S＆Tech Inc. RS-2024-00442484
18 Discovery of PIP5Kgamma inhibitor for treatment of Parkinson's disease
Small molecules Parkinson's disease PIP5Kγ Hit K.MEDI hub RS-2023-00283494
19 Development of a novel c.Abl and LRRK2 dual inhibitor for Parkinson’s Disease Treatment
Small molecules Parkinson's disease c.Abl/LRRK2 Phase 1 1ST Biotherapeutics Inc. RS-2023-00283009
20 Non.clinical development of ALS disease treatment using a small molecule compound that inhibits aggregation of SOD1 protein
Small molecules Amyotrophic Lateral Sclerosis SOD1 Preclinical PRG S&Tech Inc. RS-2023-00258714
21 Discovery of Lead Candidates for Parkinson’s disease targeting novel TAS2R GPCR
Small molecules Parkinson's disease TAS2R Lead DIGMBIO RS-2023-00219269
22 Development of a lead compound for preventing Parkinson’s disease using small compounds with inhibitory mechanism of initial alpha-synuclein aggregation
Small molecules Parkinson's disease α-synuclein Hit Hanyang University HN21C1258
23 Lead identification of ASK1 inhibitor as a therapeutic agent for Parkinson’s disease
Small molecules Parkinson's disease ASK1 Lead Korea Research Institute of Chemical Technology HN21C1139
24 Development of small molecule LRRK2 inhibitor for Parkinson’s disease treatment
Small molecules Parkinson's disease LRRK2 Candidate Whan In Pharm. Co., Ltd. HN21C0655
25 Discovery of Lead Compounds for the Treatment of Progressive Supranuclear Palsy by Controlling 4R Tauopathy
Small molecules Progressive supranuclear palsy, 4R tauopathies 4R tau oligomer Lead Korea Institute of Science and Technology HN21C0315
26 Development of lead compounds as antidepressant having both α2 adrenergic antagonist and NDRI activities
Small molecules Major depressive disorder A2 adrenergic, NDRI Hit Kyung Hee University HN21C1076
BACK